Research ExplorerPublicationsStereotactic body radiotherapy for oligo-metastatic liver di...

Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control

Standard

Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. / Klement, R J; Guckenberger, M; Alheid, H; Allgäuer, M; Becker, G; Blanck, O; Boda-Heggemann, J; Brunner, T; Duma, M; Gerum, S; Habermehl, D; Hildebrandt, G; Lewitzki, V; Ostheimer, C; Papachristofilou, A; Petersen, C; Schneider, T; Semrau, R; Wachter, S; Andratschke, N.

In: RADIOTHER ONCOL, Vol. 123, No. 2, 05.2017, p. 227-233.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Klement, RJ, Guckenberger, M, Alheid, H, Allgäuer, M, Becker, G, Blanck, O, Boda-Heggemann, J, Brunner, T, Duma, M, Gerum, S, Habermehl, D, Hildebrandt, G, Lewitzki, V, Ostheimer, C, Papachristofilou, A, Petersen, C, Schneider, T, Semrau, R, Wachter, S & Andratschke, N 2017, 'Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control', RADIOTHER ONCOL, vol. 123, no. 2, pp. 227-233. https://doi.org/10.1016/j.radonc.2017.01.013

APA

Klement, R. J., Guckenberger, M., Alheid, H., Allgäuer, M., Becker, G., Blanck, O., Boda-Heggemann, J., Brunner, T., Duma, M., Gerum, S., Habermehl, D., Hildebrandt, G., Lewitzki, V., Ostheimer, C., Papachristofilou, A., Petersen, C., Schneider, T., Semrau, R., Wachter, S., & Andratschke, N. (2017). Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. RADIOTHER ONCOL, 123(2), 227-233. https://doi.org/10.1016/j.radonc.2017.01.013

Vancouver

Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. RADIOTHER ONCOL. 2017 May;123(2):227-233. https://doi.org/10.1016/j.radonc.2017.01.013

Bibtex

@article{0159c1d99e134829a001e36e7a3a22ad,
title = "Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control",
abstract = "INTRODUCTION: Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology.METHODS: 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database. Histology was considered through random effects in semi-parametric and parametric frailty models. Dose prescriptions were parametrized by conversion to the maximum biologically effective dose using alpha/beta of 10Gy (BEDmax).RESULTS: After adjusting for histology, BEDmax was the strongest predictor of TCP. Larger PTV volumes, chemotherapy prior to SBRT and simple motion management techniques predicted significantly lower TCP. The model predicted a BED of 209±67Gy10 necessary for 90% TCP at 2years with no prior chemotherapy, but 286±78Gy10 when chemotherapy had been given. Breast cancer metastases were significantly more responsive to SBRT compared to other histologies with 90% TCP at 2years achievable with BEDmax of 157±80Gy10 or 80±62Gy10 with and without prior chemotherapy, respectively.CONCLUSIONS: Besides dose, histology and pretreatment chemotherapy were important factors influencing local TCP in this large cohort of liver metastases. After adjusting for prior chemotherapy, our data add to the emerging evidence that breast cancer metastases do respond better to hypofractionated SBRT compared to other histologies.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Breast Neoplasms/secondary, Dose-Response Relationship, Radiation, Female, Humans, Liver Neoplasms/drug therapy, Male, Middle Aged, Proportional Hazards Models, Radiosurgery/methods, Young Adult",
author = "Klement, {R J} and M Guckenberger and H Alheid and M Allg{\"a}uer and G Becker and O Blanck and J Boda-Heggemann and T Brunner and M Duma and S Gerum and D Habermehl and G Hildebrandt and V Lewitzki and C Ostheimer and A Papachristofilou and C Petersen and T Schneider and R Semrau and S Wachter and N Andratschke",
note = "Copyright {\textcopyright} 2017 Elsevier B.V. All rights reserved.",
year = "2017",
month = may,
doi = "10.1016/j.radonc.2017.01.013",
language = "English",
volume = "123",
pages = "227--233",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control

AU - Klement, R J

AU - Guckenberger, M

AU - Alheid, H

AU - Allgäuer, M

AU - Becker, G

AU - Blanck, O

AU - Boda-Heggemann, J

AU - Brunner, T

AU - Duma, M

AU - Gerum, S

AU - Habermehl, D

AU - Hildebrandt, G

AU - Lewitzki, V

AU - Ostheimer, C

AU - Papachristofilou, A

AU - Petersen, C

AU - Schneider, T

AU - Semrau, R

AU - Wachter, S

AU - Andratschke, N

N1 - Copyright © 2017 Elsevier B.V. All rights reserved.

PY - 2017/5

Y1 - 2017/5

N2 - INTRODUCTION: Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology.METHODS: 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database. Histology was considered through random effects in semi-parametric and parametric frailty models. Dose prescriptions were parametrized by conversion to the maximum biologically effective dose using alpha/beta of 10Gy (BEDmax).RESULTS: After adjusting for histology, BEDmax was the strongest predictor of TCP. Larger PTV volumes, chemotherapy prior to SBRT and simple motion management techniques predicted significantly lower TCP. The model predicted a BED of 209±67Gy10 necessary for 90% TCP at 2years with no prior chemotherapy, but 286±78Gy10 when chemotherapy had been given. Breast cancer metastases were significantly more responsive to SBRT compared to other histologies with 90% TCP at 2years achievable with BEDmax of 157±80Gy10 or 80±62Gy10 with and without prior chemotherapy, respectively.CONCLUSIONS: Besides dose, histology and pretreatment chemotherapy were important factors influencing local TCP in this large cohort of liver metastases. After adjusting for prior chemotherapy, our data add to the emerging evidence that breast cancer metastases do respond better to hypofractionated SBRT compared to other histologies.

AB - INTRODUCTION: Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology.METHODS: 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database. Histology was considered through random effects in semi-parametric and parametric frailty models. Dose prescriptions were parametrized by conversion to the maximum biologically effective dose using alpha/beta of 10Gy (BEDmax).RESULTS: After adjusting for histology, BEDmax was the strongest predictor of TCP. Larger PTV volumes, chemotherapy prior to SBRT and simple motion management techniques predicted significantly lower TCP. The model predicted a BED of 209±67Gy10 necessary for 90% TCP at 2years with no prior chemotherapy, but 286±78Gy10 when chemotherapy had been given. Breast cancer metastases were significantly more responsive to SBRT compared to other histologies with 90% TCP at 2years achievable with BEDmax of 157±80Gy10 or 80±62Gy10 with and without prior chemotherapy, respectively.CONCLUSIONS: Besides dose, histology and pretreatment chemotherapy were important factors influencing local TCP in this large cohort of liver metastases. After adjusting for prior chemotherapy, our data add to the emerging evidence that breast cancer metastases do respond better to hypofractionated SBRT compared to other histologies.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Breast Neoplasms/secondary

KW - Dose-Response Relationship, Radiation

KW - Female

KW - Humans

KW - Liver Neoplasms/drug therapy

KW - Male

KW - Middle Aged

KW - Proportional Hazards Models

KW - Radiosurgery/methods

KW - Young Adult

U2 - 10.1016/j.radonc.2017.01.013

DO - 10.1016/j.radonc.2017.01.013

M3 - SCORING: Journal article

C2 - 28274491

VL - 123

SP - 227

EP - 233

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

IS - 2

ER -